22nd November 2011
Health Information Announces Investment from MVM Life Science Partners
Health Information, the dominant provider of point of dispensing messaging in the UK, announces that it has secured a first round of funding from MVM Life Sciences LLP.
Read this article
15th September 2011
Horizon Discovery Announces £11.3 Million Fundraising
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, has announced that it has completed a second closing of its Series C funding round, realising a cumulative total of £11.3m, with MVM Life Sciences LLP leading the second closing.
Read this article
28th July 2011
AccuVein Secures $22.5 million Series B Financing through MVM Life Science Partners and Bessemer Venture Partners
AccuVein Inc., a global leader in medical imaging technology and the creator of the AV300, the world’s first hand-held, non-contact vein illumination device, has announced that it has secured $22.5 million in a Series B financing.
Read this article
12th July 2011
Tarsa Therapeutics Advances its Oral Calcitonin for the Treatment and Prevention of Postmenopausal Osteoporosis
Tarsa Therapeutics has announced that the positive Phase III data from the registration trial of its oral calcitonin drug has been accepted for an oral presentation at the ASBMR Annual Meeting, patient enrolment is complete in the Phase II proof-of-concept prevention study in 120 postmenopausal women and Tarsa has closed an additional financing of $24.5 million.
Read this article
28th June 2011
Argenta Signs Integrated Services Agreement with Pulmagen Therapeutics
Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects.
Read this article
News Archive
Last 5 Articles | Next 5 Articles
22nd October 2010Aegerion Pharmaceuticals Announces Pricing of Initial Public Offering
BRIDGEWATER, N.J., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share, before underwriting discounts and commissions. All shares are being sold by the company. Aegerion has granted the underwriters an option for 30 days to purchase up to an additional 750,000 shares at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The common stock will trade on the NASDAQ under the symbol "AEGR."
Leerink Swann LLC and Lazard Capital Markets LLC are acting as joint book-running managers for the offering. Needham & Company, LLC, Canaccord Genuity Inc. and Collins Stewart LLC are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Leerink Swann LLC by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, or by calling toll free (800) 808-7525, Ext. 4814, or Lazard Capital Markets LLC by mail at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, Attention: Syndicate Department, or by calling toll free (800) 542-0970
| Associated Links Visit Aegerion Pharmaceuticals, Inc. |
Downloads Full Press Release |